{"id":251792,"date":"2024-02-13T00:00:00","date_gmt":"2024-02-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidne0003-biopharma-polycystic-kidney-disease-epidemiology-mature\/"},"modified":"2026-05-01T11:23:37","modified_gmt":"2026-05-01T11:23:37","slug":"epidne0003-biopharma-polycystic-kidney-disease-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidne0003-biopharma-polycystic-kidney-disease-epidemiology-mature-markets\/","title":{"rendered":"Polycystic Kidney Disease &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of polycystic kidney disease (<abbr title=\"polycystic kidney disease\">PKD<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the prevalence and incidence of <abbr title=\"polycystic kidney disease\">PKD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"polycystic kidney disease\">PKD<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"polycystic kidney disease\">PKD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts 11 <abbr title=\"polycystic kidney disease\">PKD<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of autosomal dominant polycystic kidney disease (<abbr data-abbreviation-entity=\"7142\" title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of definite <abbr data-abbreviation-entity=\"7142\" title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of likely <abbr data-abbreviation-entity=\"7142\" title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of mild <abbr title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of moderate <abbr title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of severe <abbr title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of low-risk rapid-progression <abbr title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of intermediate-risk rapid-progression <abbr title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of high-risk rapid-progression <abbr title=\"autosomal dominant polycystic kidney disease\">ADPKD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of autosomal recessive polycystic kidney disease (<abbr data-abbreviation-entity=\"10258\" title=\"autosomal recessive polycystic kidney disease\">ARPKD<\/abbr>).<\/li>\n<li>Diagnosed incident cases of <abbr data-abbreviation-entity=\"10258\" title=\"autosomal recessive polycystic kidney disease\">ARPKD<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251792","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251792\/revisions"}],"predecessor-version":[{"id":293490,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251792\/revisions\/293490"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}